Affordable Prescriptions for Patients Through Promoting Competition Act of 2019

Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 This bill prohibits, subject to certain exceptions, the practice of product hopping, which is presumed when a drug manufacturer obtains removal of a drug from the Food and Drug Administration's approved drug list, discontinues a drug, or markets a reformulation of an already approved drug during a certain period after which the manufacturer has been notified that a competing drug manufacturer has applied for generic drug approval.